Dewpoint Therapeutics and Mitsubishi Tanabe link on ALS treatment
Pharmaceutical Technology
DECEMBER 5, 2024
Dewpoint Therapeutics and MTPC have entered a strategic research partnership focusing on the development of TDP-43 small molecule c-mod.
Thu.Dec 05, 2024
147 
Atlas doubles down on ‘disciplined’ biotech investing with latest fundraise
Bio Pharma Dive
DECEMBER 5, 2024
The venture firm’s “modest” $450 million fund, a lower total than some of its peers recently raised, reflects lessons learned after Atlas grew too quickly, partner Bruce Booth wrote in a blog post.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Protecting Your Muscle Mass Is Vital For Healthy Aging – Here’s Why
AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 5, 2024
Skeletal muscle fibers (multinucleated cells) with their nerve connections. (Ed Reschke/Stone/Getty Images) We’d all like to live longer; at least, I would. But what about enjoying the time we have while we’re here and living healthier? Over the past century, human life expectancy has dramatically increased for a variety of reasons.
GSK taps a startup for shot at Alzheimer’s drug
Bio Pharma Dive
DECEMBER 5, 2024
The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a startup that launched less than four years ago.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
December 5, 2024: Nudge Pragmatic Trial Finds No Improvement in Adherence to Cardiovascular Medications
Rethinking Clinical Trials
DECEMBER 5, 2024
Dr. Michael Ho and Dr. Sheana Bull, principal investigators for Nudge Text message–based reminders to patients who delayed refilling their cardiovascular medications did not improve medication adherence compared with usual care in the recently completed Nudge trial. The results of the study were published online ahead of print in JAMA. Nudge, an NIH Collaboratory Trial, was a randomized, pragmatic clinical trial embedded in 3 healthcare systems testing a variety of text messaging strategies to
Nuvig pulls in $161M to make better immune drugs
Bio Pharma Dive
DECEMBER 5, 2024
The company is developing treatments to rebalance, rather than suppress, immune function in people with inflammatory conditions, starting with an antibody near Phase 2 testing.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
India takes centre-stage in clinical trials for HIV/AIDS drug
AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 5, 2024
India has taken centre-stage in clinical trials for HIV/AIDS drug as there are several ongoing clinical trials in India focused on advancing HIV treatment. These trials are investigating new drug candidates, therapies, and approaches to manage HIV more effectively and potentially cure it.
LEO Pharma’s eczema cream gains MHRA marketing authorisation
Pharmaceutical Technology
DECEMBER 5, 2024
LEO Pharma has gained marketing authorisation from the MHRA for Anzupgo to treat chronic hand eczema (CHE) in Great Britain.
NICE endorses Neuraxpharm’s ublituximab for treating MS
Pharma Times
DECEMBER 5, 2024
New antibody therapy shows promise in managing condition
FDA approves AstraZeneca’s Imfinzi to treat LS-SCLC
Pharmaceutical Technology
DECEMBER 5, 2024
The US FDA has approved AstraZeneca's Imfinzi (durvalumab), to treat limited-stage small cell lung cancer (LS-SCLC) in the adult population.
Teva’s Ajovy shows positive results in preventing pediatric migraines
Pharma Times
DECEMBER 5, 2024
Phase 3 trial indicates significant efficacy and safety for children and adolescents
AstraZeneca scores FDA nod for Imfinzi as first immunotherapy for limited-stage small cell lung cancer
Fierce Pharma
DECEMBER 5, 2024
AstraZeneca has picked off another label expansion for cancer blockbuster Imfinzi as the FDA has blessed it for limited-stage small cell lung cancer.
Still no clear motive in UnitedHealth CEO killing
pharmaphorum
DECEMBER 5, 2024
Investigations continue into the death of UnitedHealth chief executive Brian Thompson, who was shot and killed by an unknown assailant in New York
On an investment spree, Lilly will spend $3B to expand newly acquired injectables plant in Wisconsin
Fierce Pharma
DECEMBER 5, 2024
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Mounjaro cleared for NHS use, but patients may have to wait
pharmaphorum
DECEMBER 5, 2024
Many patients can expect a long wait for access to Eli Lilly's obesity shot Mounjaro, even though it has been recommended for routine NHS use by NICE
Novartis' latest attempt to fend off MSN's Entresto generic falls short on appeal
Fierce Pharma
DECEMBER 5, 2024
Novartis’ latest effort to block a generic challenger to blockbuster heart med Entresto has come up short, this time in a federal appeals court. | The U.S. Court of Appeals for the Federal Circuit sided with a prior ruling that denied Novartis' motion seeking an injunction to prevent MSN's generic rival from launching.
Novartis bid to block generic Entresto in US suffers setback
pharmaphorum
DECEMBER 5, 2024
An appeals court in the US has declined to overturn an attempt by Novartis to block the launch of a generic of its heart failure blockbuster Entresto.
Amgen’s GLP-1 Drug MariTide Delivers Solid Weight Loss Results in Trial but Fails to Impress Analysts
XTalks
DECEMBER 5, 2024
Amgen announced positive results from a Phase II clinical trial evaluating its investigational obesity drug MariTide (maridebart cafraglutide, formerly AMG 133) for the treatment of obesity and overweight in both diabetic and non-diabetic patients. Among the next generation of obesity drugs, MariTide is a top GLP-1 contender that touts the potential for enhanced efficacy and more convenient, less frequent dosing.
Merus grabs first-in-class US approval for NRG1 cancer drug
pharmaphorum
DECEMBER 5, 2024
Merus has its first approval for a commercial product, getting the go-ahead from the FDA for Bizengri, a first-in-class therapy for cancer
Amgen rolls out $1B investment to build new drug substance plant in NC's biopharma hotbed
Fierce Pharma
DECEMBER 5, 2024
Amid a flurry of manufacturing activity in the state this year, Amgen is the latest drugmaker to bolster its production footprint in North Carolina. | Amgen is laying out $1 billion to build a second drug substance facility in Holly Springs, North Carolina. Together with Amgen’s existing facility in the town, the company’s investments in Holly Springs are slated to create a total of 370 new jobs.
FDA clears AZ's Imfinzi for aggressive lung cancer
pharmaphorum
DECEMBER 5, 2024
AstraZeneca's Imfinzi becomes the first cancer immunotherapy to be FDA-approved for limited-stage small cell lung cancer (LS-SCLC)
Amgen’s GLP-1 Drug MariTide Delivers Solid Weight Loss Results in Trial but Fails to Impress Analysts
XTalks
DECEMBER 5, 2024
Amgen announced positive results from a Phase II clinical trial evaluating its investigational obesity drug MariTide (maridebart cafraglutide, formerly AMG 133) for the treatment of obesity and overweight in both diabetic and non-diabetic patients. Among the next generation of obesity drugs, MariTide is a top GLP-1 contender that touts the potential for enhanced efficacy and more convenient, less frequent dosing.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Understanding the Lifecycle of Generic Drugs: From Development to Market Impact
Drug Patent Watch
DECEMBER 5, 2024
In the ever-evolving landscape of healthcare, generic drugs play a crucial role in providing affordable and accessible medication to millions of people worldwide. But have you ever wondered about the journey these drugs take from conception to your local pharmacy shelf?
Learning from Your Mistakes: Keeping Sites from Repeatedly Tripping Over the Same Noncompliance Issues
ACRP blog
DECEMBER 5, 2024
How can clinical trial sites decrease the most common noncompliance issues cited in regulatory inspections? It’s a big challenge to sites of all types, and one with major impacts on the safe, ethical, and efficient conduct of life-enhancing drug and device studies. Tackling this topic in a presentation on “ Detecting and Addressing the Quality Pitfalls at Study Sites ” at the ACRP 2025 conference next April in New Orleans, La., will be ACRP Fellows Jerry M.
Proactive Planning to Navigate Clinical Research Staffing Trends in 2025 | Advanced Clinical
pharmaphorum
DECEMBER 5, 2024
Explore proactive planning strategies to navigate upcoming staffing trends in clinical research by 2025 with Advanced Clinical. Stay ahead of the curve in the ever-evolving landscape of clinical research.
Fierce Pharma Asia—Sanofi's $1B manufacturing base; GSK's ADC deal, Shingrix recalibration in China
Fierce Pharma
DECEMBER 5, 2024
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Harnessing Marketing Networks in the Pharmaceutical Industry: Strategies for Success
Pharma Marketing Network
DECEMBER 5, 2024
Table of Contents Sr# Headings 1 Introduction: The Power of Marketing Networks 2 What Are Marketing Networks? 3 The Importance of Marketing Networks in Pharma 4 Building Healthcare Professional (HCP) Networks 5 Patient Advocacy Groups: A Trusted Connection 6 Digital Marketing Networks in Pharma 7 Branded Campaigns and Marketing Networks 8 Overcoming Challenges in Marketing Networks 9 The Role of Data in Strengthening Networks 10 Future Trends in Marketing Networks 11 Practical Tips for Pharma Ma
Policy and Population Health
Pharmaceutical Commerce
DECEMBER 5, 2024
Is the potential of a more formal policy integration for health issues and disease prevention a scary suggestion or a good Idea?
Money vs mindset: How the NHS can make the most of extra investment
pharmaphorum
DECEMBER 5, 2024
Discover how the NHS can optimise extra funding by balancing budget allocation with a focus on mindset and strategic choices to improve patient care and organisational efficiency.
The Advantages of New Medicare Rx Payment Plan
Pharmaceutical Commerce
DECEMBER 5, 2024
While the program could be a good option for many, it's not a panacea.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content